SCHEMBL25229347

SCHEMBL25229347

O=C(O)CCOc1cccc(/C=C/C(=O)c2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.65
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
THRB P10828 1/20 0.56
MAOB P27338 5/20 0.55
DHFR P00374 3/20 0.54
ACHE P22303 2/20 0.54
MAPT P10636 2/20 0.54
PLIN1 O60240 1/20 0.54
TNFRSF1A P19438 1/20 0.54
RECQL P46063 1/20 0.54
PLIN5 Q00G26 1/20 0.54
CYP1B1 Q16678 1/20 0.54
ABHD5 Q8WTS1 1/20 0.54
KDM4E B2RXH2 2/20 0.53
PKM P14618 1/20 0.53
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25218020 1.00 BCHE (0.65) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL31233116 1.00 BCHE (0.65) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL30383438 1.00 BCHE (0.65) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL30383059 0.93 BCHE (0.56) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL25236243 0.93 BCHE (0.56) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL30383171 0.93 BCHE (0.56) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL25279152 0.93 BCHE (0.56) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL25195492 0.91 BCHE (0.59) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL25200452 0.91 BCHE (0.59) BCHEALDH1A1LMNASMN1; SMN2THRB
SCHEMBL25190942 0.91 BCHE (0.59) BCHEALDH1A1LMNASMN1; SMN2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B BCHE 588/4885ALDH1A1 3285/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 BCHE 465/4885ALDH1A1 3081/4885LMNA 1817/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 BCHE 465/4885ALDH1A1 3081/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.